FDA Endorses Antibody to Protect Kids from RSV
The therapy was developed by Sanofi and Astrazeneca and is called Nirsevimab.
An FDA advisory panel has voted to recommend an injectable drug to prevent RSV in infants and some young toddlers. The therapy was developed by Sanofi and Astrazeneca and is called Nirsevimab. It’s designed to be given in a single shot at birth or a baby’s first season of RSV. It can also be given as a larger dose in a second RSV season in children who are highly vulnerable. Nearly every child before age two gets RSV. Most cases are mild but it’s the leading cause of hospitalization among infants. In trials, the shot was found to lower the risk of needing medical attention by 75-percent and the risk of hospitalization by 78-percent. Common side effects were rash and injection-site reactions.